GlobeNewswire·Oct 13, 2026, 4:30 PM ET

Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Zealand Pharma & Generate Biomedicines announced a collaboration on October 13, 2026, to develop AI-engineered protein therapeutics for metabolic diseases & obesity.
The partnership combines Zealand Pharma's metabolic health expertise with Generate's generative AI platform to create multispecific drug candidates.
Generate will receive a USD 30 million up-front payment & up to USD 35 million in early preclinical milestones for two initial programs.
Generate is eligible for nearly USD 1.2 billion in total milestones covering development, regulatory, & commercial stages, plus tiered royalties on future net sales.
Under the agreement terms, Generate leads research through lead-candidate selection, while Zealand Pharma manages clinical development, regulatory submissions, & worldwide commercialization.
The collaboration expands Zealand Pharma's capabilities beyond peptides & extends The Generate Platform into the obesity & metabolic disease sectors.
Legal advisors included Cooley LLP for Zealand Pharma & Ropes & Gray LLP for Generate.